Annual Report

Overview

The report describes FY2016 net sales growth to 18,085 million yen, supported by core products including GROWJECT® and Epoetin Alfa BS Inj. JCR. It highlights the development of rare-disease treatments, including Phase I/II trials of JR-141 for Hunter syndrome. The company also reports CSR activity across work environment, environmental activities, social contributions, and rare diseases.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2016-2017
Period: 1 April 2016 – 31 March 2017
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services